Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A cardio-oncology multidisciplinary team is essential for the successful delivery of patient-centred care. The roles of oncologists, haematologists, and cardiologists have been clearly articulated in literature pertaining to the creation of cardio-oncology clinics. However, the involvement of other key team members, such as pharmacists, nurses and nurse practitioners, social workers, psychologists and other allied health professionals has been less well-defined. In this review we aim to define the role of pharmacists and nurses as part of a multidisciplinary cardio-oncology team. We also discuss models of care and opportunities to expand the delivery of cardio-oncology services to further enhance outcomes for individuals with cancer, and highlight the challenges experienced by those living in regional, rural, and remote communities.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12297693 | PMC |
| http://dx.doi.org/10.1186/s40959-025-00369-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HER2-targeted therapies and cardiotoxicity: From major concern to manageable risk.
Curr Probl Cardiol
September 2025
Internal Medicine Study Program, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. Electronic address:
HER2-targeted therapies have dramatically improved outcomes for patients with HER2-positive breast cancer, but their potential for cardiotoxicity remains a critical clinical concern. Early trials reported high rates of cardiac dysfunction, particularly with concomitant anthracycline use, prompting the development of intensive cardiac monitoring strategies. However, emerging evidence suggests that most cardiotoxic events are asymptomatic, reversible, and rarely require permanent treatment discontinuation, particularly with newer agents such as antibody-drug conjugates.
View Article and Find Full Text PDFHospital pharmacists in cardio-oncology: bridging a critical gap in multidisciplinary cancer care.
Eur J Hosp Pharm
September 2025
Pharmacy Department, Hospital Clinica Biblica, San José, Costa Rica.
Cardiac resynchronization therapy in cancer patients with chemotherapy-induced cardiomyopathy: a mini review.
Heart Fail Rev
September 2025
Division of Provincial Cardiology, Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
Chemotherapy-induced cardiomyopathy (CHIC) represents a growing clinical challenge due to the increasing use of cardiotoxic treatments. These therapies can lead to progressive myocardial dysfunction, ultimately resulting in heart failure. Cardiac resynchronization therapy (CRT) has been widely investigated in selected patients with chronic heart failure; however, those with CHIC remain underrepresented in CRT trials.
View Article and Find Full Text PDFConcomitant carcinoid heart disease and patent foramen ovale: a case report and review of literature.
Cardiooncology
September 2025
Hospital Distrital de Santarém, Santarém, Portugal.
Background: Carcinoid Heart Disease (CHD) primarily affects the right heart valves, while left heart involvement is rare and often associated with a patent foramen ovale (PFO). Early identification of a PFO in CHD can be critical to patient outcomes. A 61-year-old woman with metastatic neuroendocrine tumor presented with worsening breathlessness and hypoxemia.
View Article and Find Full Text PDFBackground: Patients with primary central nervous system lymphoma (PCNSL) often require high-dose methotrexate (HD-MTX)-based regimens for effective disease control. However, the coexistence of heart failure with a reduced ejection fraction (HFrEF) poses significant challenges due to the increased risk of treatment-related cardiotoxicity and the potential exacerbation of cardiac dysfunction from fluid overload.
Main Body: This review explores current PCNSL treatment modalities and their implications for patients with HFrEF.